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Abstract
Background: Severe Acute Respiratory Syndrome coronavirus-2 (SARS-CoV-2) has challenged public health
agencies globally. In order to effectively target government responses, it is critical to identify the individuals most at
risk of coronavirus disease-19 (COVID-19), developing severe clinical signs, and mortality. We undertook a systematic
review of the literature to present the current status of scientific knowledge in these areas and describe the need
for unified global approaches, moving forwards, as well as lessons learnt for future pandemics.
Methods: Medline, Embase and Global Health were searched to the end of April 2020, as well as the Web of
Science. Search terms were specific to the SARS-CoV-2 virus and COVID-19. Comparative studies of risk factors from
any setting, population group and in any language were included. Titles, abstracts and full texts were screened by
two reviewers and extracted in duplicate into a standardised form. Data were extracted on risk factors for COVID-19
disease, severe disease, or death and were narratively and descriptively synthesised.
Results: One thousand two hundred and thirty-eight papers were identified post-deduplication. Thirty-three met
our inclusion criteria, of which 26 were from China. Six assessed the risk of contracting the disease, 20 the risk of
having severe disease and ten the risk of dying. Age, gender and co-morbidities were commonly assessed as risk
factors. The weight of evidence showed increasing age to be associated with severe disease and mortality, and
general comorbidities with mortality. Only seven studies presented multivariable analyses and power was generally
limited. A wide range of definitions were used for disease severity.
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Conclusions: The volume of literature generated in the short time since the appearance of SARS-CoV-2 has been
considerable. Many studies have sought to document the risk factors for COVID-19 disease, disease severity and
mortality; age was the only risk factor based on robust studies and with a consistent body of evidence. Mechanistic
studies are required to understand why age is such an important risk factor. At the start of pandemics, large,
standardised, studies that use multivariable analyses are urgently needed so that the populations most at risk can
be rapidly protected.
Registration: This review was registered on PROSPERO as CRD42020177714.
Keywords: Coronavirus, COVID-19, Systematic review, Review, Risk factors, Morbidity, Mortality
Introduction
The world is currently experiencing a pandemic of
coronavirus disease (COVID-19) caused by the Severe
Acute Respiratory Syndrome coronavirus-2 (SARS-
CoV-2) [1]. The risk of morbidity and mortality from
the virus is strongly stratified, with poor clinical out-
comes considered more likely in certain vulnerable
groups. For example, studies from different countries
have established that older age groups are at
increased risk of death [2, 3].
The ability to identity the population groups most at
risk from the virus has manifold public health purposes.
Using such data, stratified vaccination policies for
governmental delivery can be designed, similar to those
for influenza [4]. It may also be possible to prioritise
more active monitoring of groups more at risk of clinical
deterioration, and facilitate access to healthcare facilities
by early identification of the individuals most likely to
progress to severe disease who would thus be in need of
intensive care and ventilation. Official advice can be is-
sued to vulnerable groups to let them know that they
are more at risk from SARS-CoV-2 virus, to promote be-
haviour modification [5, 6]. Such population groups can
also be the target of more formalised ‘segment and
shield’ approaches: having divided the population into
groups that present with similar health care concerns
and needs (segmenting) it is possible to determine which
groups require extra protection by reducing interaction
with other groups (shielding), whilst relaxing restrictions
for the rest of the population [7]. Potential public health
policies along this route have been critiqued, however,
on an inclusivity basis, particularly due to the unin-
tended harmful consequences to already marginalised
groups [8].
In the UK, vulnerable people were stratified into two
tiers early on- 30th March 2020 (Table 1); those at risk
of severe illness, who were advised to be particularly
stringent with social distancing measures, and those
within that group at further risk – described as ‘shielded’
individuals – who were advised to self-isolate and were
provided with additional advice [9–12]. The former cat-
egorisation was based on the groups targeted for
National Health Service programmes on influenza vac-
cination and the latter on clinical consensus. These
strata were deliberately broad, to maximise the number
of individuals protected. As the evidence evolves – e.g.
regarding whether the development of lesions in the car-
diovascular system contributes meaningfully to disease
pathogenesis in patients with and without pre-existing
cardiovascular conditions [13] – there is the opportunity
for the categorisation of risk of COVID-19 and serious
outcomes from COVID-19 to become more evidence-
based.
During epidemics and pandemics of emerging infec-
tious diseases, it is critical to rapidly and accurately iden-
tify the populations most at risk. In the case of COVID-
19, we undertook a systematic review and quality assess-
ment of the rapidly-evolving global literature in this area,
looking at three key outcomes: COVID-19 disease, dis-
ease severity, and mortality from the condition. Any po-
tential risk factors, populations, and study designs were
included. Arising from our findings, we highlight key
knowledge gaps in the current literature and the need
for unified global approaches moving forwards, particu-
larly for the next pandemic.
Materials and methods
Literature search
We systematically searched Medline, Embase, and Glo-
bal Health (all via the Ovid platform), in addition to the
Web of Science, for published literature between 1st No-
vember 2019 and 26th March 2020; then subsequently
updated this search for a later period to 29th April. In
order to avoid missing publications on risk factors, only
terms specific to the virus and the disease were used,
which were combined with ‘or’:
 ‘coronavirus’
 ‘covid-19’
 ‘severe acute respiratory syndrome coronavirus 2’
 ‘2019-nCoV-2’
 ‘SARS-CoV-2’
 ‘acute respiratory syndrome’
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No limits or filters were applied to the search. The
same search terms were used across all databases.
Reference lists of included papers and review articles
were also searched, as was the grey literature of public
health reports for the 26 countries with the highest
numbers of reported patients with COVID-19 at the end
of April 2020, for other countries it was assumed there
would be insufficient numbers of cases to yield relevant
data.
Eligibility criteria and study selection
The following inclusion and exclusion criteria were ap-
plied to the search results.
Inclusion criteria:
 Studies had to provide comparative data on risk
factors of any kind for disease (versus no disease),
severe disease (versus milder disease) or mortality
(versus survival),
 Studies were eligible if they presented data on
patients with polymerase chain reaction (PCR)-
confirmed SARS-CoV-2 infections. There was con-
siderable variation in case definitions between stud-
ies, but PCR testing was the gold standard test for
active disease at the start of the pandemic [14], and
other testing methods such as Loop-Mediated Iso-
thermal Amplification or serological tests were not
included,
 Any study design,
 Any population group,
 Any language of publication.
Exclusion criteria:
 No comparator group included in the study,
 Publication concerned other viruses and diseases,
 Work conducted in animals or in vitro,
 Study population was less than 20 individuals.
Two reviewers independently screened all titles, ab-
stracts and full texts for both literature searches. Dis-
crepancies were resolved by consensus. In all cases
where studies were published in any language other than
English, with no translations available, these were
screened by at least one additional reviewer, with further
quality control by another member of the reviewing
team.
Data extraction
Three reviewers independently double-extracted the




 Type of study,
 Country,
 Study population,
Table 1 UK risk groupings for COVID-19 disease on 30th March 2020
At risk of severe illness Shielding
Aged 70 or older (regardless of medical conditions)
Aged under 70 anda
Chronic (long-term) mild to moderate respiratory diseases, such as
asthma, COPD, emphysema or bronchitis
People with severe chest conditions such as cystic fibrosis or severe
asthma (requiring hospital admissions or courses of steroid tablets)
Chronic heart disease, such as heart failure
Chronic kidney disease People with severe diseases of body systems, such as severe kidney
disease (dialysis)
Chronic liver disease, such as hepatitis
Chronic neurological conditions, such as Parkinson’s disease, motor
neurone disease, MS, a learning disability or cerebral palsy
Diabetes
A weakened immune system as the result of conditions such as HIV
and AIDS, or medicines such as steroid tablets
People who have received an organ transplant and remain on ongoing
immunosuppression medication
People with cancer who are undergoing active chemotherapy or
radiotherapy
People with cancers of the blood or bone marrow such as leukaemia who
are at any stage of treatment
Being seriously overweight (a BMI of 40 or above)
Those who are pregnant
Data taken from sources [9–11]. aThese groupings represent individuals advised to get a yearly influenza vaccine as an adult for medical reasons. BMI body mass
index, COPD chronic obstructive pulmonary disease, MS multiple sclerosis
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 Overall number in study,
 Number with PCR confirmed SARS-CoV-2,
 Median age of participants/age range,
 Sex ratio,
 Analytical method used,
 Factors adjusted for during the analysis,
 Whether disease, disease severity, or death (or a
combination of these) was the outcome of interest,
 The definition of disease severity used, if applicable,
 The risk factors analysed and the direction of effect.
Results were compared and discrepancies resolved by
discussion. Data from studies published in languages other
than English, at this stage only the Chinese language, were
extracted by two additional reviewers, with further quality
control by another member of the reviewing team.
Quality assessment
Two reviewers independently assessed the quality of in-
cluded studies. Studies published in languages other
than English were quality assessed by two additional re-
viewers, with further quality control by another member
of the reviewing team. Assessments were undertaken
from the perspective of the objectives of this review,
which were not necessarily identical to the objectives of
the underlying studies. The quality of included studies
was assessed using a checklist adapted from Downs and
Black [15], as per the guidance issued by Deeks et al.
[16] When assessing the power of studies, the minimum
sample size required to detect a relative increase in risk
of 10% from a statistically conservative baseline of 50%
among the unexposed was calculated at different powers
using the Kelsey method within Epi Info, software made
available by the United States Center for Disease Control
[17]. This 10% value was based on governmental discus-
sions taking place in the UK at the time the review took
place. An alpha of 5% was set as the standard. Pragmat-
ically, we assumed only two strata and a ratio of 1:1 be-
tween exposure strata. Different thresholds were used
for case-control studies and for cohort or cross-sectional
studies. These criteria were scored from 0 (< 70% power)
to 5 (> 99% power). We considered results sufficient ad-
justed for confounding if they adjusted for at least the
minimal variable set of age, sex, ethnicity and any meas-
ure of comorbidities. For ethnically homogenous popula-
tions, the need for adjustment for ethnicity was
discounted. If two analyses were presented within a sin-
gle paper with different quality scores, the most conser-
vative score was retained. Studies were not excluded on
the basis of the quality assessment.
Analysis and synthesis
Studies were grouped on the basis of the outcome exam-
ined (disease, disease severity, mortality) and then the
risk factors examined. Results were classified on the
basis of whether they presented evidence as to the ex-
posure under study being a risk factor, taking into ac-
count the number of individuals exposed. Where studies
focussed on a single risk factor of interest with adjust-
ment for confounding, we extracted all data on potential
risks in order to maximise the value of our dataset
(whilst accepting that such mutually adjusted estimates
for covariates may remain confounded even if that for
the primary exposure does not) [18]. As there was sub-
stantial heterogeneity in study design, reporting, and the
risk factors examined, we present a detailed descriptive
summary and narrative synthesis of our findings, rather
than a meta-analysis.
Registration and reporting
This review was registered on PROSPERO as
CRD42020177714 and is reported according to the PRIS
MA guidelines.
Results
Two thousand eight hundred and sixty-eight hits were
obtained by the searches across the two dates (Fig. 1).
After de-duplication across the different databases, this
was reduced to 1238. Thirty studies were included at the
extraction stage; the main reasons for exclusion were
small numbers of participants and studies not having a
comparator population. From the grey literature an add-
itional report was included and two studies were identi-
fied from reference lists.
Included studies are presented in Table 2. Twenty-
nine of the 33 studies were conducted in China, with
one each from France, Italy, Singapore and a combined
study from England, Wales and Northern Ireland. Six
were studies with COVID-19 disease as the outcome, 20
of disease severity and ten of mortality. One additional
study looked at a combined outcome of disease severity
and mortality.
Quality assessment
Included studies were generally too small to detect a 10%
increase in risk of disease, disease severity, or mortality
(Table 3). One study among the 33 was assessed to have
95% power and two others 99%; all were large, national,
investigations. As 26 studies were purely descriptive or
presented univariable analysis only, there was no adjust-
ment for confounding. Remaining studies with a regres-
sion component did not adjust for our minimal
confounder set. Only nine studies provided estimates of
the random variability of effect estimates. The majority of
studies ascertained exposure information from clinical re-
cords, which would have collected data prospectively and
thus with limited recall bias. Blinding of outcome and ex-
posure recording by investigators was not documented. In
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the case of certain disease severity outcomes, such as
admittance to intensive care units (ICU), variability in
thresholds for reaching these outcomes is likely to exist
between settings and clinicians.
Risk factors for disease
Six studies compared the likelihood of having
COVID-19 to other infectious conditions (Table 4).
Of note, as testing strategies were largely focussed
on hospitalised individuals i.e. those displaying
noticeable symptoms, studies were of the likelihood
of COVID-19 disease, rather than more broadly of
SARS-CoV-2 infection (and particularly of severe
disease, although patients with mild and symptom-
atic infection were also reported to be hospitalised
in some studies for the purposes of isolation or
Fig. 1 PRISMA flow chart of selection
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Table 2 Included studies
Author Type of
study
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21 Univariable N/A Disease
severity
Severe meets any of
the following criteria-
respiratory distress,
RR ≥ 30 breaths/min;





to 48 h in pulmonary
imaging.
Cheng [24] Case-control China Patients presenting with
fever diagnosed with
pneumonia by specialists
























Italy Hospitalised in ICU across
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273 Univariable N/A Disease
severity
Severe met at least one
of the following
conditions: a) shortness
of breath, RR≥ 30
times/min, b) oxygen
saturation (resting
state) ≤93%, or c)
PaO2/FiO2≤ 300
mmHg., in addition to
positive SARS-CoV-2
RNA nucleic acid test
by Reverse transcription
polymerase chain reac-
tion, fever, or other re-
spiratory symptoms
Flook et al. BMC Infectious Diseases          (2021) 21:342 Page 6 of 23
Table 2 Included studies (Continued)
Author Type of
study
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Table 2 Included studies (Continued)
Author Type of
study
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patients had one of the
following criteria: (a) re-
spiratory distress with
respiratory frequency≥
30/min; (b) pulse oxim-
eter oxygen satur-
ation≤ 93% at rest; and
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observation). Age and sex were key foci as potential
risk factors, comparing patients with COVID-19 to
either: a) SARS-CoV or Middle Eastern Respiratory
Syndrome (MERS), or b) other forms of pneumonia.
Generally, sex ratios were skewed such that men
were over-represented among those with disease. In
England, Northern Ireland, and Wales, Asian and
Black individuals were found to be at increased risk
of COVID-19 in descriptive analyses, with 15.4 and
10.7% of patients falling into these groupings,
respectively, versus 5.8 and 2.8% of individuals with
other viral pneumonia [30]. Higher body mass index
(BMI) was also suggested to be a risk factor with
two descriptive analyses, for example in the Intensive
Care National Audit and Research Centre (ICNARC)
report 31.2% of COVID-19 patients had a BMI of
30- < 40, versus 23.5% of people with other viral
pneumonia [30, 37]. Given the large, national, scope
of the ICNARC dataset, results from it are particu-
larly likely to be reliable.
Risk factors for severe disease
Among the 20 studies of risk factors for severe versus
milder disease and one of a mixed outcome (severe disease
and death), a wide array of definitions of severity were
used, such as ICU admission, the need for mechanical
ventilation, and various measures of respiration and oxy-
genation (Table 2). Many risk factors were examined
(Table 5). As well as potential demographic risks (age, sex,
ethnicity), behavioural traits (smoking) and broad clinical
factors (BMI, infectious diseases) were analysed. Large
numbers of papers sought to explore the implications of
different comorbidities on the risk of severe COVID-19,
particularly respiratory and cardiovascular conditions.
The least equivocal evidence was presented for age as
a risk factor, including four studies where it was an inde-
pendent risk in a multivariable regression model [19, 20,
31, 36]. The clearest analysis to present age data (i.e.
which used different comparison groups) was a univari-
able regression model where individuals 65 years and
over had 3.26 times the hazard rate of ARDS than those
Table 2 Included studies (Continued)
Author Type of
study
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severity
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ARDS acute respiratory distress syndrome, BMI body mass index, CDC Center for Disease Control and Prevention, CT computed tomography, FiO2 inspired oxygen
fraction, ICNARC intensive care national audit and research centre, ICU intensive care unit, MERS Middle Eastern Respiratory Syndrome, N/A not applicable, PaO2
arterial partial pressure of oxygen, RR respiratory rate, SARS severe acute respiratory syndrome, SpO2 oxygen saturation
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under 65 [44]. Eight studies suggested that diabetes
could be a risk factor [19, 31, 36, 39, 41, 43, 44, 50], six
hypertension [31, 36, 41, 43, 44, 50], and four the pres-
ence of unspecified comorbidities) [39, 41, 48, 50], but
the balance of evidence for these co-morbidities being
risk factors was generally inconclusive. Many other fac-
tors were examined by one study, often with small num-
bers of individuals with the condition. None of the
included studies for disease severity were assessed to
have been powered to detect a 10% increase in effect
size.
Risk factors for mortality
Ten studies examined risk factors for mortality, often by
nesting case-control studies within prospective or retro-
spective cohorts (Table 6). Among these studies, many
included statistical testing, but none presented an ad-
justed regression model for the risk factors considered.
Eight studies examined age and all provided evidence
for it being a risk factor for mortality [21, 25, 27, 35, 44–
47], although none adjusted for other factors, such as co-
morbidities. Age groups from 50 upwards were considered
particularly at risk. In the single regression analysis, the
hazard rate for death in those 65 years or over was esti-
mated to be six times that of individuals under 65 [44].
The evidence was similarly consistent for general comor-
bidities (albeit all the studies were descriptive); among
individuals who died, comorbidities were 1.5 to 2.8 times
more common than among those who survived [21, 35,
46, 47, 51]. Specific comorbidities were discussed in sev-
eral studies, generally under overarching classifications
such as ‘cardiovascular disease’ or ‘diabetes’, with more
specific definitions not provided. Evidence was more
equivocal, but still in favour, of hypertension [3, 21, 25, 27,
47, 51], cardiovascular disease [21, 25, 35, 45, 47, 51], dia-
betes [21, 25, 45–47, 51], and chronic respiratory/lung dis-
eases being risk factors (references presented for studies
in support only) [21, 45, 51]. Of these studies, data from
two well-powered, national-level studies from China sup-
ported cardiovascular disease and diabetes as risk factors
for mortality from COVID-19 [25, 45].
Discussion
In this systematic review of risk factors for COVID-19
disease, disease severity and mortality, we document 33
comparative studies examining sociodemographic,
behavioural and clinical exposures. Age and sex were
very commonly examined; a wide array of comorbidities
have also been considered.
Within the synthesised evidence, risk factors for mor-
tality were the clearest, plausibly partly because this out-
come is easy to define. Increasing age (different studies
presented different thresholds, but being over 50 years of
age was common) was an uncontested risk factor. Five
Table 4 Potential risk factors for disease
Potential risk
factor
Study supports risk Study does not support risk or is neutral
Age Patients older than those with COVID-19 and younger than those with
MERS (descriptive) [40]
Younger ages (median 45 years) in patients with COVID-19 than other
pneumonia (median 61) (statistical test) [22]
Increasing risk of positivity for SARS-CoV-2 among COVID-19 suspects (on
the basis of symptoms/contact tracing) with age (odds ratio 1.02) but un
clear categorisation of age (multivariable regression) [33]
Median age 60 years in those with COVID-19 and 61 in
those with other viral pneumonia (descriptive) [30]
Mean age 50 years in COVID-19 patients vs.
44 in individuals with other pneumonia (statistical test) [24]
Sex Sex ratio skewed towards men for COVID-19, akin to MERS but not SARS
(descriptive) [40]
Sex ratio skewed towards men for COVID-19 versus other viral pneumonia
(descriptive) [30]
Greater proportion male in COVID-19 versus other pneumonia, although
small sample size and thus low statistical certainty (statistical test) [24]
Increasing risk of positivity for SARS-CoV-2 among COVID-19 suspects (on
the basis of symptoms/contact tracing) among males versus female (odds
ratio 1.16) (logistic regression) [33]
Sex distribution similar amongst patients
with COVID-19 and other pneumonia (statis
tical test) [22]
Ethnicity Higher percentage of Black and Asian individuals amongst COVID-19 pa
tients than patients with other viral pneumonias (descriptive) [30]
Index of multiple
deprivation
Distribution of deprivation similar across




Greater proportion of COVID-19 patients had higher body mass index than
individuals with other pneumonia (descriptive) [37]
Greater proportion of COVID-19 patients had higher body mass index than
individuals with other viral pneumonia (descriptive) [30]
Pregnancy Percentage of women who were pregnant
similar across COVID-19 and other viral pneu
monia (descriptive) [30]
MERS middle eastern respiratory syndrome, SARS severe acute respiratory syndrome
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Table 5 Potential risk factors for disease severity
Potential risk factor Study supports risk Study does not support risk or is neutral
Sex Odds ratio for severe disease 3.68 for men compared to
women (multivariable regression) [36]
Odds ratio for invasive mechanical ventilation 2.83 for men
compared to women (multivariable regression) [37]
Females less likely to be admitted to ICU, require
mechanical ventilation, or die; odds ratio 0.61 (multivariable
logistic regression) [31]
Sex distribution similar in severe and non-severe disease
(descriptive) [30, 49]
Sex distribution similar in severe and non-severe disease
(statistical test) [23, 26, 28, 29, 32, 34, 38, 39, 41–44, 48–50]
Sex distribution similar in severe and non-severe disease
(multivariable regression) [19, 20]
Age Averagea 61 years severe disease, 45 otherwise (statistical
test) [38]
Averagea 61 years severe disease, 52 years moderate disease
(statistical test) [23]
Averagea 56 years severe disease, 44 years mild disease
(statistical test) [39]
Median 67 years acute respiratory distress syndrome, 52
severe, 45 mild (statistical test) [42]
Median 64 years severe patients, 52 years otherwise
(statistical test) [48]
Mean 61 years severe, otherwise 40 (statistical test) [50]
Median 71 years SpO2 < 90%, 37 years SpO2 ≥ 90% (statistical
test) [43]
Median 66 years patients in ICU, 51 otherwise (statistical
test) [41]
Median 54 years patients in ICU, 41 otherwise (statistical
test) [26]
65 years and over 3.26 times the hazard rate of ARDS than
those under 65 (univariable regression) [44]
Age associated with ICU admission, odds ratio 1.06 but
unclear for what categorisation of age (multivariable
regression) [20]
Distribution of age did not differ by disease severity
(descriptive) [30, 34, 49]
Distribution of age did not differ by disease severity
(statistical test) [28, 29, 32]
Confidence interval for effect of age (categorisation
unclear) crosses the null (multivariable regression) [37]
Mean 56 years severe disease, 45 years mild disease; odds
ratio 1.06 but unclear categorisation of age (multivariable
regression) [36]
Mean 63 years severe disease, 41 years mild disease; odds
ratio 1.08 but unclear categorisation of age (multivariable
regression) [19]
Older individuals more likely to be admitted to ICU, require
mechanical ventilation, or die; odds ratio 1.05, categories of
age unclear (multivariable logistic regression) [31]
Ethnicity 76.3% of individuals receiving basic respiratory support were
White versus 65.6% receiving advanced respiratory support;
Asian and Black ethnicities appear most at risk of severe
disease (England, Northern Ireland and Wales; descriptive) [30]
Distribution of disease severity similar across ethnic
groups (Chinese, Malay, Indian, other – with small
numbers in groups other than Chinese; study in
Singapore; descriptive) [26]
Deprivation Distribution across deprivation categories similar
(descriptive) [30]
Pregnancy Distribution in pregnant and non-pregnant individuals
similar across disease severity (descriptive) [30]
Smoking 100% of current smokers had severe disease, but only six
individuals smoked [50]
Distribution in current and non-current smokers similar
across disease severity (descriptive), only three individuals
smoked [39]
Distribution in current and non-current smokers similar
across disease severity (statistical test); small numbers
who smoked [29]
Distribution in historical/current and non-smokers similar
across disease severity (statistical test) [36, 48]
Body mass index ≥35 kg/m2 risk factor versus < 25 kg/m2 for invasive
mechanical ventilation; odds ratio 7.36. Results for other strata
cross the null (multivariable regression) [37]
Increasing body mass index increased risk; odds ratio 1.17
(categorisation unclear) [19]
Distribution of disease severity similar across body mass
index categories (descriptive) [30]
Any/other comorbidity Presence of comorbidity more common among those with
severe disease (statistical test) [39, 41, 48, 50]
Distribution with and without condition similar across
disease severity (statistical test) [23, 29, 36]
Distribution with and without comorbidities not
otherwise considered in the study similar across disease
severity (statistical test) [50]
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Table 5 Potential risk factors for disease severity (Continued)
Potential risk factor Study supports risk Study does not support risk or is neutral
Distribution with and without condition similar across




Presence of comorbidity more common among those with
severe disease (descriptive) [39]
Presence of comorbidity more common among those with
severe disease (statistical test) [19, 36, 41, 43, 50]
Distribution with and without condition similar across
disease severity (descriptive) [30, 44]
Distribution with and without condition similar across
disease severity (statistical test) [29, 48]
Hypertension Presence of comorbidity more common among those with
severe disease (statistical test) [41, 43, 50]
Hazard ratio of ARDS 1.82 in those with the condition versus
those without (univariable regression) [44]
Odds ratio of severe disease 2.71 in those with the condition
versus those without (multivariable regression) [36]
Odds ratio of being admitted to ICU, require mechanical
ventilation, or die 1.89 in those with the condition versus
those without (multivariable regression) [31]
Distribution with and without condition similar across
disease severity (descriptive) [39]
Distribution with and without condition similar across
disease severity (statistical test); one study with small
numbers with the condition [23, 29, 42, 48]
Confidence interval in presence and absence of condition
crosses the null (multivariable regression) [19]
Confidence interval in presence and absence of condition
crosses the null (multivariable regression, result
borderline) [37]
Diabetes Presence of comorbidity more common among those with
severe disease (descriptive) [39]
Presence of comorbidity more common among those with
severe disease (statistical test) [19, 36, 41, 43, 50]
Hazard ratio of ARDS 2.34 in those with the condition versus
those without (univariable regression) [44]
Odds ratio of being admitted to ICU, require mechanical
ventilation, or die 2.21 in those with the condition versus
those without (multivariable regression) [31]
Distribution with and without condition similar across
disease severity (statistical test); small numbers with
condition [23]
Distribution with and without condition similar across
disease severity (statistical test) [29, 48]
Distribution with and without condition similar across
disease severity (statistical test, borderline result) [42]
Confidence interval in presence and absence of condition
crosses the null (multivariable regression) [37]
Respiratory/pulmonary
disease
Distribution with and without condition similar across
disease severity (descriptive) [30, 39]
Asthma Distribution with and without condition similar across





Presence of comorbidity more common among those with
severe disease (descriptive); small numbers with condition
[39]
Presence of comorbidity more common among those with
severe disease (statistical test); both studies have small
numbers with the condition [41, 50]
Odds ratio of being admitted to ICU, require mechanical
ventilation, or die 3.40 in those with the condition versus
those without (multivariable regression) [31]
Distribution with and without condition similar across
disease severity (statistical test); small numbers with
condition [29, 43, 48]
Pulmonary tuberculosis Distribution with and without condition similar across
disease severity (statistical test); small numbers with
condition [48]
Malignancy Presence of comorbidity more common among those with
severe disease (statistical test); small numbers with condition
[39]
Presence of comorbidity more common among those with
severe disease (statistical test) [36, 42, 50]
Presence of comorbidity more common among those with
severe disease (multivariable analysis) [31]
Distribution with and without condition similar across
disease severity (descriptive) [30]
Distribution with and without condition similar across
disease severity (statistical test) [41]
Distribution with and without condition similar across
disease severity (statistical test); small numbers with
condition [19, 29, 43]
Cerebrovascular disease Presence of comorbidity more common among those with
severe disease (statistical test) [41]
Arrhythmia Distribution with and without condition similar across
disease severity (statistical test); small numbers with the
condition [48]
Cerebral infarction Distribution with and without condition similar across
disease severity (statistical test) [42]
Stroke Distribution with and without condition similar across
disease severity (statistical test); small numbers with
condition [48]
Aorta sclerosis Distribution with and without condition similar across
disease severity (statistical test); small numbers with
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studies also presented evidence for the presence of any
comorbidities being a risk factor [21, 35, 46, 47, 51], with
none demonstrating evidence against. Given the increas-
ing prevalence of comorbidities with age, the lack of
adjustment for confounding in these studies likely over-
emphasises the effect size of each risk factor. We note
that work subsequent to our literature search documents
an independent effect of age on COVID-19 mortality
from overall comorbidities, as measured by the Charlson
Comorbidity Index Score, but not vice-versa [52].
Table 5 Potential risk factors for disease severity (Continued)




Presence of comorbidity more common among those with
severe disease (statistical test) [42]
Distribution with and without condition similar across
disease severity (descriptive) [30]
Distribution with and without condition similar across




Distribution with and without condition similar across
disease severity (statistical test); one study has small
numbers of patients with the condition [36, 48]
Chronic liver disease Distribution with and without condition similar across
disease severity (descriptive), sometimes small numbers
with condition [19, 30, 39]
Distribution with and without condition similar across
disease severity (statistical test) [36, 41]
Distribution with and without condition similar across
disease severity (statistical test); small numbers with
condition [29, 50]
Fatty liver and abnormal
liver function
Distribution with and without condition similar across
disease severity (statistical test) [48]
Hyperlipidaemia Distribution with and without condition similar across
disease severity (statistical test) [48]
Dyslipidemia Confidence interval in presence and absence of condition
crosses the null (multivariable regression) [37]
Chronic gastritis/gastric
ulcer
Distribution with and without condition similar across
disease severity (statistical test) [48]
Cholelithiasis Distribution with and without condition similar across
disease severity (statistical test) [48]
Urolithiasis Distribution with and without condition similar across
disease severity (statistical test); small numbers with
condition [48]
Thyroid diseases Distribution with and without condition similar across
disease severity (statistical test); small numbers with the
condition [48]
Electrolyte imbalance Presence of comorbidity more common among those with
severe disease (statistical test); small numbers with condition
[48]
Agglomerative disease Distribution with and without condition similar across
disease severity (descriptive); small numbers with the
condition [39]
Immunocompromised Distribution with and without condition similar across
disease severity (descriptive) [30]
Chronic hepatitis Distribution with and without condition similar across
disease severity (statistical test); small numbers with
condition [43]
HIV Distribution with and without condition similar across
disease severity (statistical test); small numbers with
condition [41]
Living without assistance Distribution with and without condition similar across
disease severity (descriptive) [30]
One study included death in a combined measure of disease severity [31]. aUnclear as to whether mean, median or mode. ARDS acute respiratory distress
syndrome, ICU intensive care unit, SpO2 oxygen saturation
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Table 6 Potential risk factors for mortality
Potential risk factor Study supports risk Study does not support risk or is neutral
Sex Men more at risk (descriptive) [21] Sex distribution similar amongst patients who died and
survived (descriptive) [25, 35, 46, 47]
Confidence interval for males versus females crosses the
null (univariable regression) [44]
Age Over 60 years particularly at risk (descriptive) [21]
8% case fatality ratio in 70–79 year olds and 14.8% in those
over 80. Overall figure 2.3% (descriptive) [45]
Median age in those who died 52 years, 65 years among
survivors (descriptive) [46]
Over 50 years of age particularly at risk- 1.3% died 50–59
years, 3.6% 60–69 years, 8.0% 70–79 years, 14.8% 80 years
plus; less than 1% all other age groups (descriptive) [25]
Risk begins to increase at approximately 50 years (statistical
test, but graphical presentation) [35]
Median age in those who died 68 years, among those who
survived 55 (statistical test) [47]
Over 61 years, increasing per 10 year age group (statistical
test) [27]
65 years and older 6.17 the hazard rate of those under 65
(univariable regression) [44]
Smoking Proportion of smokers similar among those who died
versus those who did not (descriptive); one study had small
numbers of smokers [21, 46]
Distribution of current smokers similar among survivors and
non-survivors (univariable regression analysis, not included
in multivariable model) [51]
Pregnancy Proportion of women who were pregnant similar amongst
patients who died versus survived (descriptive) [21]
Any comorbidity Presence of any comorbidity more common among those
dying (descriptive) [21, 35, 46, 47, 51]
Hypertension Presence of condition more common among those dying
(descriptive) [3, 21, 25, 27]
Presence of condition more common among those dying
(statistical test) [47, 51]
Confidence interval for individuals with and without the
condition crosses the null (univariable regression) [44]
Cardiovascular disease/
chronic heart disease
Presence of condition more common among those dying
(descriptive) [21, 25, 35, 45]
Presence of condition more common among those dying
(statistical test) [47, 51]
Distribution dying in presence and absence of comorbidity
similar (descriptive), sometimes small numbers with the
condition [44, 46]
Diabetes Presence of condition more common among those dying
(descriptive) [21, 25, 45, 46]
Presence of condition more common among those dying
(statistical test) [47, 51]
Confidence interval for individuals with and without the




Presence of condition more common among those dying
(descriptive) [21, 45]
Presence of condition more common among those dying
(statistical test) [51]




Presence of condition more common among those dying
(descriptive) [25]
Malignancy Presence of condition more common among those dying
(descriptive) [3, 25]
Distribution dying in presence and absence of comorbidity
similar (descriptive), sometimes small numbers with the
condition [46, 47, 51]
Cerebral infarction/
cerebrovascular disease
Presence of condition more common among those dying
(descriptive) [46]
Distribution dying in presence and absence of comorbidity
similar (statistical test); small numbers with the condition [47]
Chronic gastritis Distribution dying in presence and absence of comorbidity
similar (statistical test); small numbers with the condition [47]
Chronic kidney disease Presence of condition more common among those dying
(statistical test); small numbers with the condition [51]
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Another study published outside of the time range of
our search found both age and an array of comorbidities,
each analysed separately (chronic cardiac disease,
chronic pulmonary disease, chronic kidney disease,
chronic neurological disease, dementia, malignancy,
moderate/severe liver disease; and obesity), to be inde-
pendent risk factors (as well as sex) [53].
Risk factors for severe disease were more complex
to synthesise, likely due to the mixed array of out-
come measures that can also be prone to observer
bias. The impact of age was very commonly assessed,
generally showing evidence in favour of this being a
risk factor (with a similar age spectrum to the mortal-
ity data). Ethnicity was studied in two publica-
tions internationally [26, 30], with mixed results. We
note that such findings are likely to be highly
context-specific, given that ethnicity acts as a proxy
for a series of sociodemographic factors that are
highly relevant to the spread of an infectious condi-
tion (as well as, perhaps, some biological traits).
Studies of risk factors for COVID-19 disease have been
complicated by testing strategies globally, which have
largely been concentrated on severe disease. As our
knowledge of the full symptom spectrum of the disease
moves forward, it will be possible to have a broader case
definition that does not solely focus on viral testing, and
thus the ability for more generalised complementary
studies. Additionally, serological surveys assessing the
history of infection with SARS-CoV-2 in different popu-
lation groups will allow the identification of risk factors
for infection, whether symptomatic or not. Both ethni-
city (Black and Asian individuals at higher risk; from a
single study in England, Northern Ireland and Wales)
[30] and higher BMI were found to be associated with
disease severity within the included literature [30, 37],
again from descriptive studies only. While these studies
were not eligible for our review, we note a series of re-
ports from non-comparative studies documenting the
potential influence of ethnicity on the likelihood of get-
ting COVID-19 e.g. the work of Price-Haywood from
the US [52]. Male sex was reasonably consistently shown
to be a risk factor for presence of COVID-19 but not
with severity of disease or mortality [24, 30, 40]. As with
ethnicity, socioeconomic and behavioural factors make
this association likely to vary between settings.
In considering the role of comorbidities in COVID-19,
it is important to consider the underlying pathology of
the virus. Respiratory coronaviruses associated with the
common cold in immunocompetent people generally
affect only cells in the upper respiratory tract (URT),
whereas the previously discovered highly pathogenic cor-
onaviruses SARS-CoV and MERS-CoV affect cells in the
URT and lower respiratory tract (LRT). SARS-CoV-2
has been shown to do the same [54], and one of the host
cell receptors it targets is Angiotensin-Converting En-
zyme 2 (ACE2), with a second major receptor being
Transmembrane Serine Protease 2 (TMPRSS2) [55].
SARS-CoV-2 can infect all the major cell types in the re-
spiratory tract – type I and type II pneumocytes, alveolar
macrophages and endothelial cells [56, 57]. This infec-
tion leads to cell death, with significant leaking of fluid
into the alveolar spaces (pulmonary oedema), which
compromises gas exchange [58], eventually leading to
ARDS. The inflammatory response adds aggregation of
repair proteins such as fibrin, which can lead to creation
of hyaline membranes which further reduces the surface
available for gas exchange [58]. Subsequently, inflamma-
tory cells are activated, recruited by release or exposure
of cytokines such as the interleukins (IL) 1β and 6,
monocyte chemoattractant protein-1 [56], and proteins
of the extracellular matrix, as well as upregulation of the
complement system. Inflammatory cells release
cytokines which have systemic effects, eventually leading
to disseminated intravascular coagulation (DIC),
hypotensive shock and metabolic disturbances if not
checked [58].
This pathogenesis therefore offers several points where
co-morbidities may exacerbate the process. The target
receptor TMPRSS2 is modulated in response to air pol-
lution and in autoimmune conditions such as asthma
[55], which may affect the number of receptors available
for SARS-CoV-2 to target, and ACE2 is involved in the
renin-angiotensin system (RAS) which controls blood
pressure. Viral interference causes dysfunction, which
leads to a pro-inflammatory state and increased vascular
permeability in response to changes in vascular contrac-
tion and sodium homeostasis – exacerbating the effect
from the physical damage to the affected cells [58]. Con-
ditions causing hypertension – both primary and
secondary to renal disease, endocrine dysfunctions such
Table 6 Potential risk factors for mortality (Continued)
Potential risk factor Study supports risk Study does not support risk or is neutral
Dementia Distribution dying in presence and absence of comorbidity
similar (descriptive); small numbers with the condition [46]
Malnutrition Distribution dying in presence and absence of comorbidity
similar (descriptive); small numbers with the condition [46]
Hepatitis B virus
infection
Distribution dying in presence and absence of comorbidity
similar (descriptive) [21]
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as hypothyroidism, cardiovascular dysfunction such as
arteriosclerosis, or neurological dysfunctions such as
acute stress – also affect the RAS [58], meaning that
these conditions might be expected to exacerbate path-
ology caused by SARS-CoV-2. Any condition creating a
pro-inflammatory state, such as type II diabetes or pre-
existing infection, or involving autoimmunity, such as
type I diabetes, might also be expected to contribute to
increased pathology. There is also the direct effect of cell
damage – if the target tissues are already damaged this
reduces ‘spare’ capacity and therefore the leeway for
adaptation to allow the host to continue to maintain
homeostasis whilst still being able to eliminate the
pathogen and repair the damage. The need for inflam-
matory cells to clear the infection is also a potential area
of interface with comorbidities e.g. conditions such as
unsuppressed HIV infection, or congenital deficiencies,
or cancer malignancies; or the administration of im-
munosuppressant drugs such as chemotherapy for can-
cer or steroids.
The effect of ageing was particularly strong within our
review, both in terms of the magnitude of effect esti-
mates and the number of studies presenting evidence.
As well as the above impact of comorbidities, we note
that the host’s age may influence pathogenesis, both in
terms of the likelihood of having various comorbidities,
and also due to its effect on the immune system. Indeed,
the immune system becomes less effective over time
(immunosenescence), which affects the quality and num-
ber of immune system cells generated [59]. Given the
scale of the impact of age documented within this re-
view, it seems unlikely that its effect can be explained by
a single or a small number of comorbidities which are
yet to be detected. This opens up the need to explore
biological markers, for example ACE2 [60], and markers
of immunosenescence.
The strengths of our review include its systematic ap-
proach and broad use of search terms to avoid missing
studies. We additionally present a quality assessment to
aid the interpretation of the strength of the evidence. In
some instances, included publications may have focussed
on one specific outcome, whereas our quality assessment
took the perspective of the outcomes extracted for this
review. We were unable to detect instances where two
publications used the same patient populations for their
analyses, potentially over-emphasising certain findings.
Given the global nature of the pandemic, our review in-
cludes studies from around the world, albeit with a large
preponderance from China, including studies conducted
early after the emergence of SARS-CoV-2 when the at-
risk population was predominantly those who had con-
tact with Huanan seafood market and their contacts,
and not necessarily representative of the general popula-
tion. We note a particular lack of studies from the
African continent and the Americas, which may have
implications for generalisability. Given the rapidly evolv-
ing literature on COVID-19, we also note our exclusion
of studies published online after April 2020 (and the
time period in which the surrounding text was written),
for example the Dai report on cancer as a risk factor
[61] and our exclusion of preprints (which was under-
taken to ensure that all included studies had undergone
an external quality assessment prior to inclusion).
Across the included publications, variability in study
design, exposure and outcome measurement, and ana-
lyses made exact syntheses of effect sizes across different
risk factors very difficult. Measures of disease severity
varied, e.g. admission to ICUs or clinical parameters
such as percentage oxygen saturation of the blood. Even
measures such as admission to ICU can be subjective
and may be time-, clinician-, and health systems-
dependent. If severity is recorded at admission, risk fac-
tors may reflect issues associated with delayed access to
healthcare, which may differ between settings and
healthcare systems. It is also important to note that, in
some studies of disease severity, mild disease included
both people who were hospitalised with symptoms and
asymptomatic individuals identified through contact tra-
cing. Generally, analyses were descriptive or univariable
and thus did not control for confounding. As docu-
mented above, this may be particularly problematic
when it comes to separating the impact of age and the
presence of comorbidities, as well as for identifying
which comorbidities truly increase risk, given that many
patients may have multi-morbidity.
The implications of our findings are two-fold for
COVID-19, firstly for current public health practice and
secondly for the design of future studies. We flag a num-
ber of factors of interest that should be considered by
governments and public health agencies when designing
shielding strategies and the targeting of future vaccines,
as well as in mathematical modelling projecting the
likely impact of the pandemic over time. We note, how-
ever, the need for sensitive handling of population
groups deemed to be at higher risk, and how such label-
ling does not devolve responsibility from public bodies
to these individuals for their own welfare [8]. Some pub-
lic health agencies are now including reporting of poten-
tial risk factors in their routine outputs, including ICNA
RC (included in this review) [30] and the newer
European Centre for Disease Prevention and Control
reports, which were released after this review was
conducted [62].
Our review demonstrates both the volume of literature
that can be published within only a few months since
the appearance of an emerging infectious disease, and
the need for co-ordinated approaches to such pathogens.
Global efforts using national datasets are hugely valuable
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in systematically determining the aetiology of a disease,
particularly to detect smaller effect sizes. Determination
of the exact threshold of important risk depends on pub-
lic perceptions of the disease [63], as well as policy
needs. Data collection should be standardised where
possible, e.g. by using consistent definitions of outcomes
and the treatment of exposures (for example for hyper-
tension, given that blood pressure is continuous). (For
COVID-19 we note both the valuable World Health
Organization interim guidelines on its management in
providing consistent approaches for testing and the def-
inition of ARDS [14], and that platforms such as the
International Severe Acute Respiratory and Emerging In-
fections Consortium (ISARIC) have aimed to facilitate
such standardisation [64].) The choice of comparison
groups should also merit careful consideration; compari-
son to other forms of the same condition (e.g. SARS and
MERS for COVID-19), although interesting, provide lit-
tle information about risk groups to be currently acted
upon. Where key potential risk factors of interest, such
as deprivation, are linked to both the disease of interest
and the comparator condition, this limits the inferences
possible. Saying this, studies of COVID-19 with the
comparator group of other forms of viral pneumonia are
a useful complement to studies using a general popula-
tion comparator, as they show whether people with par-
ticular risk factors are at risk over and above what they
might experience from ‘normal’ respiratory viruses,
which might inform the level of additional precautions
they could consider taking.
Finally, appropriately adjusted multivariable analyses
should be prioritised, in order to separate the impli-
cations of different risk factors and to infer true
causal relationships, for example exploring specific
markers of comorbidity severity and control, such as
the use of specific medications. We can then make
the recommendations for shielding criteria more tar-
geted, meaning that the public can be made more
aware of the risk factors that are likely to have clin-
ical significance and adapt their behaviour accord-
ingly. Early clinical studies during pandemics are
critically important and published rapidly under ex-
tremely difficult circumstances, but we would argue
that high-quality epidemiological studies should also
be seen as a priority, and that emergency response
plans should include provision of appropriate epi-
demiological and statistical expertise.
Conclusions
The volume of literature generated in the short time
since the appearance of SARS-CoV-2 has been consider-
able. Many studies have sought to document the risk
factors for COVID-19 disease, disease severity and mor-
tality. Age was the only risk factor based on robust
studies and with a consistent body of evidence. Mechan-
istic studies are required to understand why age is such
an important risk factor. At the start of pandemics, large,
standardised, studies using multivariable analyses – e.g.
using national surveillance data – are urgently needed in
order to inform stratified approaches to rapidly protect-
ing the population groups most at risk.
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